Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for bile duct cancer: combo therapy aims to boost survival

NCT ID NCT07437287

Not yet recruiting Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check survival at 6 months and track side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms extrahepatic bile duct carcinoma gallbladder carcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER (BTC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHM - CHU La Timone

    Marseille, France

  • APHP - Hopital Beaujon

    Paris, France

  • CHU Brest

    Brest, France

  • CHU Estaing

    Clermont-Ferrand, France

  • CHU Grenoble Alpes

    Grenoble, France

  • CHU Hotel Dieu

    Nantes, France

  • CHU Lille

    Lille, France

  • CHU Montpellier - Hôpital Saint Eloi

    Montpellier, France

  • CHU Poitiers

    Poitiers, France

  • CHU Tours

    Tours, France

  • CHU de Bordeaux - Hopital Haut Leveque

    Bordeaux, France

  • CHU de Dijon

    Dijon, France

  • CHU de Lyon

    Lyon, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre François Baclesse

    Caen, France

  • Centre Léon Bérard

    Lyon, France

  • Centre Paul Strauss

    Strasbourg, France

  • Hopital du Confluent

    Nantes, France

  • Institut Curie

    Paris, France

  • Institut Jean Godinot

    Reims, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • Institut de cancérologie de l'Ouest - Site Paul Papin

    Angers, 49933, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.